Norwood, Mass. — October 30, 2025 — Leads & Copy — Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) plans to offer and sell shares of its common stock or pre-funded warrants in an underwritten registered public offering, with all securities sold by Corbus.
The offering’s completion, size, and terms are uncertain due to market conditions. Corbus intends to use the net proceeds to fund clinical development and for general corporate purposes.
Jefferies LLC and Piper Sandler & Co. are joint book-running managers. Corbus may grant underwriters an option to purchase additional shares. A registration statement is effective as of March 20, 2024. The offering will be made only by means of a prospectus.
Corbus Pharmaceuticals is an oncology and obesity company committed to bringing innovative scientific approaches to well-understood biological pathways. Its pipeline includes CRB-701, CRB-601, and CRB-913. The company is headquartered in Norwood, Massachusetts.
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
Source: Corbus Pharmaceuticals Holdings, Inc.
